GondolaBio is a startup based in the United States, most recent round Series B, 1 tracked investor.
Based in the United States, GondolaBio is a startup founded in 2024. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
GondolaBio is a clinical-stage biopharmaceutical company developing therapeutics for genetic diseases, focusing on early-stage research and development of treatments for rare genetic conditions such as erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.